Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects.
作者信息
Newhouse Paul A
机构信息
Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN.
US Department of Veterans Affairs, Tennessee Valley Health Systems, Geriatric Research Education and Clinical Center, Nashville, TN.
出版信息
Nicotine Tob Res. 2019 Feb 18;21(3):345-348. doi: 10.1093/ntr/nty189.
Abstract
摘要
相似文献
1
Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects.
Nicotine Tob Res. 2019 Feb 18;21(3):345-348. doi: 10.1093/ntr/nty189.
2
The heart cell in silico: successes, failures and prospects.
Novartis Found Symp. 2002;247:182-94; discussion 194-7, 198-206, 244-52.
3
DPP IV inhibitors: successes, failures and future prospects.
Diabetes Metab Syndr. 2011 Apr-Jun;5(2):105-12. doi: 10.1016/j.dsx.2012.02.017. Epub 2012 Apr 5.
4
[Prevention of cardiovascular diseases in Russia: successes, failures, prospects].
Ter Arkh. 2004;76(6):22-4.
5
The wonderland of neuronal nicotinic acetylcholine receptors.
Biochem Pharmacol. 2018 May;151:214-225. doi: 10.1016/j.bcp.2017.12.008. Epub 2017 Dec 14.
6
Targeting proteases: successes, failures and future prospects.
Nat Rev Drug Discov. 2006 Sep;5(9):785-99. doi: 10.1038/nrd2092.
7
Editorial: Successes, failures and prospects of the anti-smoking programme.
Med J Aust. 1975 Nov 29;2(22):815-6.
8
Mutant onco-proteins as drug targets: successes, failures, and future prospects.
Curr Opin Genet Dev. 2011 Feb;21(1):29-33. doi: 10.1016/j.gde.2010.12.002. Epub 2011 Jan 12.
9
Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.
Drugs. 2016 Nov;76(17):1601-1623. doi: 10.1007/s40265-016-0659-z.
10
Antibacterial drug development program successes and failures: a pharmacometric explanation.
Curr Opin Pharmacol. 2017 Oct;36:1-7. doi: 10.1016/j.coph.2017.06.002. Epub 2017 Jul 5.
引用本文的文献
1
Challenges in legitimizing further measures against smoking in jurisdictions with robust infrastructure for tobacco control: how far can the authorities allow themselves to go?
Harm Reduct J. 2024 Feb 7;21(1):33. doi: 10.1186/s12954-024-00951-w.
2
Nicotine-mediated effects in neuronal and mouse models of synucleinopathy.
Front Neurosci. 2023 Aug 31;17:1239009. doi: 10.3389/fnins.2023.1239009. eCollection 2023.
3
The Basal Forebrain Cholinergic Nuclei and Their Relevance to Schizophrenia and Other Psychotic Disorders.
Front Psychiatry. 2022 Jul 6;13:909961. doi: 10.3389/fpsyt.2022.909961. eCollection 2022.
4
Bio-oils from vacuum ablative pyrolysis of torrefied tobacco residues.
RSC Adv. 2020 Sep 22;10(58):34986-34995. doi: 10.1039/d0ra06014c. eCollection 2020 Sep 21.
5
Healthy Subjects With Extreme Patterns of Performance Differ in Functional Network Topology and Benefits From Nicotine.
Front Syst Neurosci. 2020 Jan 10;13:83. doi: 10.3389/fnsys.2019.00083. eCollection 2019.
本文引用的文献
1
Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression.
J Clin Psychiatry. 2018 Aug 28;79(5):18m12137. doi: 10.4088/JCP.18m12137.
2
Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.
Nicotine Tob Res. 2019 Feb 18;21(3):349-356. doi: 10.1093/ntr/nty034.
3
Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update.
Nicotine Tob Res. 2019 Feb 18;21(3):370-376. doi: 10.1093/ntr/nty116.
4
Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery.
Nicotine Tob Res. 2019 Feb 18;21(3):383-394. doi: 10.1093/ntr/nty166.
5
Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.
Nicotine Tob Res. 2019 Feb 18;21(3):357-369. doi: 10.1093/ntr/nty063.
6
Enhanced Sensory-Cognitive Processing by Activation of Nicotinic Acetylcholine Receptors.
Nicotine Tob Res. 2019 Feb 18;21(3):377-382. doi: 10.1093/ntr/nty134.
7
Recent advances in cholinergic imaging and cognitive decline-Revisiting the cholinergic hypothesis of dementia.
Curr Geriatr Rep. 2018 Mar;7(1):1-11. doi: 10.1007/s13670-018-0234-4. Epub 2018 Jan 13.
8
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.
Alzheimers Dement (N Y). 2016 Feb 4;2(1):1-12. doi: 10.1016/j.trci.2016.01.001. eCollection 2016 Jan.
9
Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression.
Neurosci Biobehav Rev. 2018 Jan;84:289-298. doi: 10.1016/j.neubiorev.2017.08.018. Epub 2017 Aug 30.
10
Cholinergic, But Not Dopaminergic or Noradrenergic, Enhancement Sharpens Visual Spatial Perception in Humans.
J Neurosci. 2017 Apr 19;37(16):4405-4415. doi: 10.1523/JNEUROSCI.2405-16.2017. Epub 2017 Mar 23.
Zotero 插件